Brought to you by 
Vernalis teams up with Tris Pharma to create cough/cold drugs
27 Apr 2021
Executive Summary
Private US drug delivery company Tris Pharma Inc. has agreed to use its technology to develop up to six new long-acting prescription cough/cold therapeutics for UK biotech Vernalis PLC to exclusively market in the US, Mexico, and Puerto Rico.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vernalis teams up with Tris Pharma to create cough/cold drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice